Clinical trial
LEA29Y (Belatacept) Emory Edmonton Protocol
NCT00468403 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00468403 |
|---|---|
| Title | LEA29Y (Belatacept) Emory Edmonton Protocol |
| Official title | Islet Transplantation in Type I Diabetes With LEA29Y (Belatacept) Maintenance Therapy (CIT-04) |
| Acronym | LEEP |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Clinical Islet Transplantation Consortium |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 1 Diabetes Mellitus |
| Intervention type | Biological, Drug, Procedure |
| Interventions | Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells |
| Enrollment | 10 |
| Start date | Oct 1, 2008 |
| Primary completion | Apr 1, 2012 |
| Completion | Apr 1, 2013 |
| First posted | May 2, 2007 |
| Last update posted | Apr 7, 2016 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: